These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30699280)
1. [Proposal for a simple scheme of direct-action antivirals for HCV treatment in a low budget public health system]. Valdez-Hernández P; Rodríguez-Aguilar EF; Páez-Zayas VM; Lizárraga-Gómez E; García-Juárez I Salud Publica Mex; 2018; 60(6):738-740. PubMed ID: 30699280 [No Abstract] [Full Text] [Related]
2. Sofosbuvir/velpatasvir (Epclusa) for hepatitis C. Med Lett Drugs Ther; 2016 Aug; 58(1501):107-8. PubMed ID: 27508349 [No Abstract] [Full Text] [Related]
3. Mavyret and Vosevi--two new combinations for chronic HCV infection. Med Lett Drugs Ther; 2017 Oct; 59(1531):166-170. PubMed ID: 28977807 [No Abstract] [Full Text] [Related]
4. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. Lalanne S; Jézéquel C; Tron C; Verdier MC; Mercerolle M; Pronier C; Guyader D; Lemaitre F Ther Drug Monit; 2020 Apr; 42(2):163-164. PubMed ID: 32195986 [TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection. Summers BB Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647 [TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. Chahine EB; Kelley D; Childs-Kean LM Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151 [TBL] [Abstract][Full Text] [Related]
10. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Asselah T; Boyer N; Saadoun D; Martinot-Peignoux M; Marcellin P Liver Int; 2016 Jan; 36 Suppl 1():47-57. PubMed ID: 26725897 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033 [TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Chahine EB; Sucher AJ; Hemstreet BA Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034 [TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776 [TBL] [Abstract][Full Text] [Related]
17. Biochemical Basis of Vosevi, a New Treatment for Hepatitis C Besandre R; Liu HW Biochemistry; 2018 Feb; 57(5):479-480. PubMed ID: 29185714 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study. Ruane P; Strasser SI; Gane EJ; Hyland RH; Shao J; Dvory-Sobol H; Tran T; Stamm LM; Brainard DM; Nyberg L; Shafran S J Viral Hepat; 2019 Jun; 26(6):770-773. PubMed ID: 30663168 [TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients. Mathur P; Kottilil S; Wilson E Antivir Ther; 2019; 24(1):1-10. PubMed ID: 30210057 [TBL] [Abstract][Full Text] [Related]